I really look forward to that as well. I should definitely revise my 27% thesis now that CVSI reported so low.
It's now possible that the quarterly revenue from CW's ABAHF products, by themselves, may have just surpassed CVSI's quarterly revenue. ABAHF had $4.1mil in Q1, which isn't very far from CVSI's $5.4mil for Q2.
ABAHF was a hell of an acquisition for CWBHF. For pretty much the exact same price as CVSI's current market cap, $65mil+, ABAHF came with more than twice the current cash of CVSI, more than twice the retail locations of CVSI, a NFL super bowl champ, intellectual property, FDA registered OTC drug products, and now we can also say similar revs to CVSI.